HANGZHOU, ZHEJIANG, CHINA, January 16, 2026 /EINPresswire.com/ -- The pharmaceutical industry is undergoing a period of ...
RICHMOND, Va., January 14, 2026 – Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced a major advancement in AI-driven Active ...
Enveda has been using AI to power its drug discovery platform for several years. The company injected $230 million into ...
"We are very excited to transition this fully-integrated API Pharmaceutical site, with its substantial reaction capacity, site infrastructure and attractive location, we are confident in the potential ...
−CDMO with a Six Decades-Long Reputation for Quality and Service Doubles Its Capacity to Take on New Development Projects− MORTON GROVE, Ill.--(BUSINESS WIRE)--Regis Technologies, Inc. today announced ...
Technological innovations throughout the past several decades have transformed the pharmaceutical manufacturing process from traditional batch production to ...
TOKYO, October 22, 2015 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today the decision to construct a new plant for manufacturing antibody active pharmaceutical ingredients (API) ...
Market valued at $72.4M in 2024, projected 7.30% CAGR growth driven by pharmaceutical API synthesis, food-grade ...
Get 30% Off All Global Market Reports With Code ONLINE30 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors” - The Business Research Company LONDON, GREATER LONDON, UNITED ...
A CDMO championing a commitment to patients may sound like lip service or branding, but truly patient-centric CDMOs offer ...
Poor API quality may often lead to delays in production and a shortage of supply. The API is, one might say, the most important element in a pharmaceutical product. Poor-quality APIs that do not meet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results